AV-105 Polymorph Selection for Stable 18F-Florbetapir Conversion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for alternative solid-state forms of florbetapir precursors with improved thermodynamic stability for the manufacturing of active pharmaceutical products, particularly to address the challenges posed by the short half-life of 18F-labeled radiopharmaceuticals like florbetapir, which require rapid conversion at PET imaging centers.
Innovation Solution
Development of two crystalline forms, Form A and Form B, of the florbetapir precursor AV-105, characterized by specific X-ray powder diffraction patterns, with Form B being identified as the more thermodynamically stable form, suitable for efficient conversion to 18F-florbetapir.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the precursor AV-105 is used for manufacturing 18F-florbetapir, then the radiopharmaceutical can be produced for PET imaging, but the short half-life of 18F requires rapid conversion and administration within about 10 hours, complicating commercial distribution
Solution Approach 1:
The patent provides pre-characterized crystalline forms of AV-105 precursor with defined XRPD patterns and thermodynamic stability properties. By establishing the precursor structure beforehand with known stability characteristics, the manufacturing process at PET imaging centers can proceed rapidly without needing to optimize crystallization conditions during the limited 10-hour window, thus resolving the contradiction between conversion speed and distribution complexity
Solution Approach 2:
The patent identifies and characterizes different polymorphic forms of AV-105 with distinct thermodynamic stability properties. By selecting specific crystalline forms with optimal stability parameters for the precursor, the patent enables reliable storage and handling during distribution while maintaining readiness for rapid 18F-labeling, thus resolving the time-critical nature of the process
2Stability of the object's composition
If alternative solid-state forms of florbetapir precursor are developed, then thermodynamic stability is improved for manufacturing, but the need to characterize and control specific crystalline forms increases process complexity
Solution Approach 1:
The patent systematically characterizes different polymorphic forms of AV-105 using XRPD patterns and thermodynamic stability measurements. By establishing clear diagnostic parameters (specific diffraction peaks at defined 2-theta angles) and stability hierarchies among forms, the patent provides a framework for controlling crystalline form without requiring complex real-time monitoring, thus resolving the contradiction between stability improvement and process complexity
Solution Approach 2:
The patent replaces complex stability control mechanisms with simple XRPD pattern matching for quality control. Instead of requiring sophisticated in-process monitoring of thermodynamic stability, the patent enables routine characterization using standard XRPD techniques with well-defined diagnostic peaks, thus resolving the contradiction between improved stability and increased complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Form B provides enhanced thermodynamic stability, ensuring reliable and efficient conversion of AV-105 to 18F-florbetapir, facilitating consistent PET imaging without the limitations of short half-life issues.
Implementation Method 1
characterized by an X-ray powder diffraction pattern using CuKα radiation comprising a peak at diffraction angle 2-theta of 20.9°
Implementation Method 2
X-ray powder diffraction pattern using CuKα radiation comprising a peak at diffraction angle 2-theta of 20.9° and one or more peaks selected from the group consisting of 3.8°, 15.1° and 21.2°
Implementation Method 3
DSC thermograms for AV-105 Form A (top line) and Form B (bottom line)
Data Source
AI summary
New polymorphic crystal forms of the following compound are disclosed:This compound is used to make florbetapir (18F).


